Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Receivables (2019 - 2025)

BioNexus Gene Lab's Receivables history spans 7 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Receivables rose 8.72% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, up 8.72%, while the annual FY2024 figure was $1.6 million, 71.37% up from the prior year.
  • Receivables for Q3 2025 was $1.6 million at BioNexus Gene Lab, down from $2.0 million in the prior quarter.
  • Across five years, Receivables topped out at $4.2 million in Q3 2021 and bottomed at $922106.0 in Q4 2023.
  • The 5-year median for Receivables is $2.2 million (2023), against an average of $2.3 million.
  • The largest annual shift saw Receivables tumbled 68.13% in 2023 before it skyrocketed 77.39% in 2025.
  • A 5-year view of Receivables shows it stood at $3.4 million in 2021, then dropped by 15.8% to $2.9 million in 2022, then crashed by 68.13% to $922106.0 in 2023, then skyrocketed by 71.37% to $1.6 million in 2024, then increased by 2.58% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Receivables are $1.6 million (Q3 2025), $2.0 million (Q2 2025), and $1.7 million (Q1 2025).